Group items tagged

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.\nBuzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Cancer Res. 2007 Jul 15;67(14):6745-52. PMID: 17638885 doi: 10.1158/0008-5472.CAN-06-4447

On June 15, 2011, the United States Food and Drug Administration informed the public that using the drug Actos, commonly prescribed in the treatment of Type 2 diabetes, has been positively associated with an increased risk of bladder cancer. Actos is manufactured by a Japanese pharmaceutical company, Takeda Pharmaceuticals, and is typically sold either as a single-ingredient product or in combination with the drug metformin. Actos is prescribed, along with diet and exercise, to help control blood sugar in adults. Initially the FDA's safety warnings were based on a five-year interim analysis of an ongoing ten year study regarding the risks for those taking Actos.